Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease European Journal of Clinical Pharmacology (2018) 74:1361–1362 https://doi.org/10.1007/s00228-018-2492-7 LETTER TO THE EDITOR The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease 1 2 3 4 1,4 4 David Pineles & Lisa Malter & Peter S. Liang & Amy Arsuaga & Brian Bosworth & David P. Hudesman & Shannon Chang Received: 29 April 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 We read with great interest a recent paper by Boone et al. [1]. penetration into our marketplace has only recently accelerated. In this 1-year observational study, the authors sought to quan- As such, we recently performed a small, prospective study tify the nocebo rate in individuals with an immune-mediated aimed at gauging IBD patients’ initial perceptions of inflammatory disease who were switched from the originator biosimilars. In 2017, we surveyed 132 adult patients with infliximab to a biosimilar for a non-medical reason. Patients IBD at two university-affiliated gastroenterology clinics regard- were provided informed consent and voluntarily agreed to ing their current impression of biosimilars. A standardized cov- transition to the infliximab biosimilar. The patients in this er sheet was included with the 14-question survey http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Clinical Pharmacology Springer Journals

The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease

Download PDF
2 pages

Loading next page...
1
 
/lp/springer_journal/the-nocebo-effect-and-patient-perceptions-of-biosimilars-in-pB1W3KZBIn

References (3)

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology
ISSN
0031-6970
eISSN
1432-1041
DOI
10.1007/s00228-018-2492-7
Publisher site
See Article on Publisher Site

Abstract

European Journal of Clinical Pharmacology (2018) 74:1361–1362 https://doi.org/10.1007/s00228-018-2492-7 LETTER TO THE EDITOR The nocebo effect and patient perceptions of biosimilars in inflammatory bowel disease 1 2 3 4 1,4 4 David Pineles & Lisa Malter & Peter S. Liang & Amy Arsuaga & Brian Bosworth & David P. Hudesman & Shannon Chang Received: 29 April 2018 / Accepted: 22 May 2018 / Published online: 31 May 2018 Springer-Verlag GmbH Germany, part of Springer Nature 2018 We read with great interest a recent paper by Boone et al. [1]. penetration into our marketplace has only recently accelerated. In this 1-year observational study, the authors sought to quan- As such, we recently performed a small, prospective study tify the nocebo rate in individuals with an immune-mediated aimed at gauging IBD patients’ initial perceptions of inflammatory disease who were switched from the originator biosimilars. In 2017, we surveyed 132 adult patients with infliximab to a biosimilar for a non-medical reason. Patients IBD at two university-affiliated gastroenterology clinics regard- were provided informed consent and voluntarily agreed to ing their current impression of biosimilars. A standardized cov- transition to the infliximab biosimilar. The patients in this er sheet was included with the 14-question survey

Journal

European Journal of Clinical Pharmacology – Springer Journals

Published: May 31, 2018

There are no references for this article.